Compare FMX & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMX | CNC |
|---|---|---|
| Founded | 1890 | 1984 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1B | 32.1B |
| IPO Year | 1998 | 2001 |
| Metric | FMX | CNC |
|---|---|---|
| Price | $128.11 | $64.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 16 |
| Target Price | ★ $113.17 | $46.75 |
| AVG Volume (30 Days) | 502.9K | ★ 3.9M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.11 |
| Revenue | N/A | ★ $194,777,000,000.00 |
| Revenue This Year | $10.20 | $8.31 |
| Revenue Next Year | $8.32 | $1.05 |
| P/E Ratio | $40.94 | ★ $20.81 |
| Revenue Growth | N/A | ★ 19.44 |
| 52 Week Low | $83.08 | $25.08 |
| 52 Week High | $130.55 | $66.55 |
| Indicator | FMX | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 62.60 |
| Support Level | $118.62 | $59.90 |
| Resistance Level | $130.55 | $66.55 |
| Average True Range (ATR) | 3.29 | 2.41 |
| MACD | -0.07 | -0.34 |
| Stochastic Oscillator | 77.19 | 74.66 |
Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up 75% of total company revenue and over 90% of profits in 2024.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.